The correlation between elevated CD73 expression and unfavorable prognosis has been established in several cancers, including PDAC.[11] Previously, we observed up‐regulation of CD73 in PDAC tissues, and we also observed a significant association between higher CD73 expression, increased programmed death‐1 receptor (PD‐L1) expression, and poorer prognosis.[11d] These findings underscore the potential of CD73 as a promising target to facilitate the efficacy of immunotherapy. This evidence concerns the gene NT5E and cancer.